Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The expedited review and approval of Sanofi-Aventis’ oncologic Jevtana (cabazitaxel) shows the power of a clearly demonstrated survival advantage to overcome regulatory hurdles.

You may also be interested in...



Case Studies In FDA's Regulatory Interpretation Of Clinical Trials

For more than 15 years, the Pink Sheet's Drug Review Profile series has looked closely at FDA approval documents, providing a long view of the pitfalls and pitches presented in the NEJM series on interpreting clinical trial results.

Lilly’s Ramucirumab Makes An Impact In Tough-To-Treat Gastric Cancer, But Will It Be Enough?

The vascular endothelial growth factor inhibitor demonstrated a 1.4 month improvement in overall survival, giving some investors the jitters but encouraging clinician experts, especially given previous targeted drug trial failures.

Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC

The most recent events in the fast-evolving castration-resistant prostate cancer field illustrate how the major advances in therapy for patients who failed chemotherapy are now spreading to the larger population of CRPC patients receiving first-line therapy for metastatic disease. The upcoming year should see Phase III results from candidates ranging from a kinase inhibitor to an antisense agent.

Related Content

Topics

UsernamePublicRestriction

Register

PS004700

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel